7 results
The primary objective of this phase III study in subjects with metastatic and/or unresectable GIST who have progressed after therapy with at least imatinib and sunitinib is to compare the treatment groups in terms of Progression-Free Survival (PFS…
The objective of this study is to to develop a selective and non-selective whole brain ASL perfusion stress test and at 3.0 Tesla based on ASL flow territory measurements.
1. What is the effect of a clinical oral dose of acetazolamide on the isocapnic hypoxic response (IHR), i.e. an exposure to hypoxia (end-tidal PO2 ~ 5.8 kPa) during 30 min? Does the agent increase the IHR as would be expected from the state of…
The primary objective will be to assess whether cerebrovascular reactivity is impaired in patients with steno-occlusive disease of the vertebrobasilar artery .
The primary objective is to evaluate the efficacy and safety of NTRA-9620 compared with placebo when added to standard of care (SOC) in pediatric subjects (aged 28 weeks post-menstrual age to 52 weeks chronological age) with SBS within 4 months from…
In a phase II study we will evaluate safety and proof-of-concept of acetazolamide in patients with aneurysmal SAH. The primary aim of this study is to evaluate whether acetazolamide improves cerebral perfusion as measured with magnetic resonance…
General aim; To dertemine if an alternating regimen of imatinib and regorafenib has sufficient activity and safety to warrant further evaluation as a first line treatment for metastatic GIST.